STAT3 is a substrate of tyrosine kinase Lyn.16 Lyn-phosphorylation-associated BCR activation also serves as an important part in the cell proliferation and apoptosis in lymphoma cells.45, 46 It has been reported that the small-molecule inhibitor to Lyn is a novel target for DLBCL patients.47, 48 Our results showed DCZ3301 inhibited Lyn activation along with decreased STAT3 activation. Here, BCR is linked to lymphoma.